We are a drug discovery company that is uniquely harnessing the power of protein dynamics, biophysics, machine learning and computational chemistry.

At Congruence, we are able to move beyond historically static drug discovery processes towards truly predictive models where the pathogenesis of disease can be corrected in silico at unprecedented speed and accuracy.

Revenir™ allows us to see proteins as others can’t – in their full and dynamic state. We generate and capture the biophysical properties of the full spectrum of protein shapes, an ensemble of protein conformers, derived from a single amino acid sequence.

Congruence Therapeutics is a drug discovery company harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning and computational chemistry.

We have a uniquely qualified team, founded by serial life sciences entrepreneur Clarissa Desjardins, PhD, most recently the founder and CEO of rare disease company Clementia Pharmaceuticals (Nasdaq: CMTA) sold to Ipsen for US$1.31 billion in 2019.  Learn more about our outstanding team below.